Published in J Immunother on September 01, 2012
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Renal-cell carcinoma. N Engl J Med (2005) 10.17
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol (2003) 2.68
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol (1991) 2.16
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int (1984) 1.76
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer (1990) 1.56
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood (1998) 1.49
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer (1988) 1.46
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Chemotherapy for renal cell carcinoma. Semin Oncol (2000) 1.29
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res (2010) 1.14
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res (2011) 1.07
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer (2005) 1.04
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer (1996) 1.02
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res (2007) 1.02
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol (2008) 1.01
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother (2005) 0.99
Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther (2009) 0.96
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother (2009) 0.95
Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother (1991) (1992) 0.93
Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer (1994) 0.87
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother (2009) 0.87
Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther (2008) 0.86
Finding markers for cancer stem cells in renal cell carcinoma: looking beyond CD133. Cell Cycle (2010) 0.85
CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer (2006) 0.83
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 0.83
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med (2010) 3.01
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood (2003) 1.93
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res (2009) 1.74
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One (2006) 1.68
Dynamic manipulation and separation of individual semiconducting and metallic nanowires. Nat Photonics (2008) 1.67
Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol (2002) 1.64
A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med (2003) 1.61
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet (2009) 1.40
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res (2008) 1.20
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 1.17
Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant (2009) 1.09
Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant (2006) 1.04
Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother (2008) 1.03
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol (2008) 1.01
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev (2003) 0.98
Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol (2010) 0.96
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother (2009) 0.95
Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol (2003) 0.95
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One (2012) 0.94
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol (2013) 0.92
A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol (2004) 0.91
A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation (2007) 0.91
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res (2005) 0.90
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother (2008) 0.89
Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant (2012) 0.89
Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res (2008) 0.88
Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother (2012) 0.88
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer (2012) 0.88
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother (2009) 0.87
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.86
Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant (2011) 0.86
High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood (2013) 0.85
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother (2009) 0.85
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 0.83
Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.83
Improving hematopoietic cell transplant outcomes in a new era of genomic research. Biol Blood Marrow Transplant (2009) 0.81
Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. PLoS One (2013) 0.81
Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol (2009) 0.79
Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opin Biol Ther (2011) 0.77
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med (2012) 0.76
Cone arrestin: deciphering the structure and functions of arrestin 4 in vision. Handb Exp Pharmacol (2014) 0.75
[The long-term outcome of trabeculectomy in advanced glaucoma]. Nippon Ganka Gakkai Zasshi (2006) 0.75
BMI Is a Better Body Proportionality Measure than the Ponderal Index and Weight-for-Length for Preterm Infants. Neonatology (2017) 0.75
Electrically switchable diffractive waveplates with metasurface aligned liquid crystals. Opt Express (2016) 0.75
[A suspected case of orbital mucormycosis]. Nippon Ganka Gakkai Zasshi (2007) 0.75
Targeting targeted therapies. Immunotherapy (2010) 0.75